Results 211 to 220 of about 419,158 (294)

Response to Mungall et al. letter to the editor on Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007–27

Expert Review of Vaccines, 2018
Raul Isturiz, Heather L. Sings, Betsy Hilton, Adriano Arguedas, Ralf-Rene Reinert, Bradford Gessner, Luis Jodar   +6 more
doaj   +1 more source

Pfizer PLASTICIZERS [PDF]

Chemical & Engineering News Archive, 1947
openaire   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, EarlyView.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. [PDF]

Front Oncol
Frontiers Production Office.
europepmc   +1 more source

Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry (AIO‐TRK‐0315)

International Journal of Cancer, EarlyView.
What's New? Estimating the risk of developing brain metastases may enable earlier diagnosis and treatment, potentially reducing morbidity and mortality. Using the prospective CRISP lung cancer registry, the authors developed and validated a point‐based classifier for the risk of developing first brain metastases in patients with advanced or metastatic ...
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller, Petra Hoffknecht, Andre Bethge, Arnd Nusch, Marcel Reiser, Christiane Bernhardt, Michael Bendel, Carolin Lennartz, Annette Fleitz, Martina Jänicke, Paula Ludwig, Annika Groth, Frank Griesinger, Michael Thomas, Wilfried E. E. Eberhardt, Martin Sebastian, for the CRISP Registry Group   +19 more
wiley   +1 more source

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). [PDF]

J Clin Oncol
Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teulé A, Custodio A, Tafuto S, La Casta A, Spada F, López C, Ibrahim T, Iranzo V, García-Alfonso P, González-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Álvarez G, Soldevilla B, Capdevila J.   +24 more
europepmc   +1 more source

Relationships between Corporate Inversions and the Tax Cuts & Jobs Act [PDF]

, 2019
Clothier, Sedona L
core   +2 more sources

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

International Journal of Cancer, EarlyView.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell, Julian Kött, Noah Zimmermann, Greta Ancker, Alexander T. Bauer, Daniel J. Smit, Glenn Geidel, Julian C. Gerwers, Thomas Renné, Sebastian A. Wohlfeil, Jochen Utikal, Stefan W. Schneider, Christoffer Gebhardt   +12 more
wiley   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source